Add time:08/21/2019         Source:sciencedirect.com

1.1. Gastric mucus from duodenal ulcer patients before and following therapy with a new antiulcer agent, Ebrotidine (cas 100981-43-9), at 400, 600 and 800 mg dose was examined for changes in the physicochemical qualities and anti-H. pylori activity.2.2. The results of physical measurements revealed that successful therapy with ebrotidine was accompanied by a 25% increase in gastric mucus viscosity, and a 20% increase in H+ retardation capacity, while its hydrophobicity increased by 11%.3.3. The enhancement in the physical properties of mucus with ebrotidine therapy were also reflected in a marked (2.6-2.9-fold) increase in the proportion of the high molecular weight form of mucin. Furthermore, following therapy with ebrotidine, the gastric mucins showed a 36% higher content of sulfate as compared to that before the therapy.4.4. Assays on the H. pylori aggregating titer of gastric mucin revealed that ebrotidine therapy at all three doses evoked a 4-fold increase in mucin anti-H. pylori activity.5.5. The data demonstrate that duodenal ulcer therapy with ebrotidine leads to a marked improvement in the protective qualities of gastric mucus essential for the maintenance of mucosal integrity and enhances the inherent mucosal defense against H. pylori infection.

We also recommend Trading Suppliers and Manufacturers of Ebrotidine (cas 100981-43-9). Pls Click Website Link as below: cas 100981-43-9 suppliers